Cedars-Sinai provides virtually every known gastroenterologic analytical procedure and treatment for digestive diseases and disorders. The Bilsborough Laboratory's integrated approach to identifying the factors driving intestinal disease benefits from the resources available at Cedars-Sinai, including inpatient and outpatient programs, state-of-the-art technology, specialized and internationally renowned physicians and a large body of research.
The Bilsborough Laboratory applies this integrated approach in our research into inflammatory bowel disease and other digestive diseases to discover and develop new therapeutics that can improve the lives of millions across the world. The research scientists and clinicians at the Bilsborough Lab are dedicated to a "bench to bedside" approach, moving discoveries out of laboratories and into effective treatments for patients with digestive diseases.
Research in the Bilsborough Lab seeks to personalize drug development and ensure that each patient receives the therapeutic treatment most suited to his or her disease. In doing so, we seek to accelerate the drug discovery process and help put new and effective therapeutic drugs on the market.
The Bilsborough Laboratory is affiliated with the Digestive Diseases Center and F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute.
Learn more about work at the Cedars-Sinai F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute by watching the video: IBD 360: Changing the Paradigm.